SOMERVILLE, Mass. - bluebird bio, Inc. (NASDAQ:BLUE), a biotechnology company focusing on gene therapies, has received notices from The Nasdaq Stock Market LLC indicating non-compliance with Nasdaq Listing Rule 5250(c)(1). The rule mandates timely filing of periodic financial reports with the Securities and Exchange Commission (SEC).
The notices, dated August 20, 2024, were issued because bluebird bio has not filed its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024, and June 30, 2024. These documents are essential for maintaining transparency with investors and regulatory compliance.
Previously, on April 26, 2024, the company disclosed a similar non-compliance issue regarding its Annual Report on Form 10-K for the year ended December 31, 2023. In response, bluebird bio submitted a plan to regain compliance by October 14, 2024, which is within the 180-day grace period allowed by Nasdaq from the original due date of the 2023 Form 10-K. The company must also file the overdue quarterly reports within this timeframe and provide an updated compliance plan by September 4, 2024.
The delay in filing is attributed to the company's decision to restate its consolidated financial statements for the year ended December 31, 2022, and for the first three quarters of both 2022 and 2023. This restatement was announced on March 26, 2024, and is currently in progress.
Despite these filing delays, there is no immediate impact on the trading of bluebird bio's common stock on the Nasdaq. The company is working expeditiously to complete the necessary filings and meet the requirements set forth by Nasdaq.
bluebird bio has been recognized for its work in gene therapy, including FDA approvals for three therapies in under two years. The company continues to focus on severe genetic diseases, leveraging its experience in ex-vivo gene therapy and lentiviral vector technologies.
This article is based on a press release statement from bluebird bio, Inc. The information provided is intended to offer a factual report on the company's current regulatory compliance status with Nasdaq and does not endorse any claims made by the company.
In other recent news, bluebird bio reported robust Q2 2024 results, with a significant increase in revenue from $16.1 million, reflecting treatments for eight Zynteglo and one Skysona patient during the quarter. Despite an anticipated dip in third-quarter revenue due to manufacturing cycle times, the biotechnology firm expects a strong rebound in the fourth quarter. The company has also revised its full-year 2024 guidance, now anticipating approximately 85 patient starts, primarily due to advanced scheduling by patients extending into the fiscal year 2025.
In terms of analyst notes, Baird remains optimistic about bluebird bio's future, maintaining its Outperform rating despite reducing its price target for the company. On the other hand, JPMorgan downgraded bluebird bio from Overweight to Neutral due to the company's second-quarter results falling short of expectations and concerns over the revised terms of the company's loan agreement with Hercules Capital (NYSE:HTGC).
The company's cash on hand is reported at $193.4 million, projected to last until Q2 2025. Over 70 qualified treatment centers are currently operational with 27 patient starts completed this year. These are some of the recent developments for bluebird bio, which continues to navigate the complex gene therapy market.
InvestingPro Insights
As bluebird bio, Inc. (NASDAQ:BLUE) navigates through its compliance challenges with Nasdaq, the company's financial health and market performance are of significant interest to investors. According to recent data from InvestingPro, the company's market capitalization stands at a modest $133.03 million. However, the company's financial metrics reflect some challenges, with a negative P/E ratio of -0.77 for the last twelve months as of Q3 2023, indicating that the company is not currently profitable.
InvestingPro Tips suggest that analysts are expecting sales growth in the current year, which could signal potential for the company's recovery. Yet, the same analysts do not anticipate bluebird bio to be profitable this year, and the company is quickly burning through its cash reserves. These factors, combined with a weak gross profit margin of -837.57% for the last twelve months as of Q3 2023, paint a concerning picture for the company's immediate financial stability.
In the stock market, bluebird bio has experienced a significant downturn. The company's stock price has been trading near its 52-week low, with a price percentage of the 52-week high at just 12.45%. Over the last month, the stock has fared poorly, with a price total return of -45.4%. This trend is consistent with the performance over the last six months, where the stock took a big hit with a total return of -45.84%.
For investors seeking a deeper understanding of bluebird bio's financial health and stock performance, InvestingPro offers additional tips that can provide more nuanced insights into the company's prospects. As of now, there are numerous additional InvestingPro Tips available that can help investors make informed decisions.
Note: The information above includes real-time data and InvestingPro Tips, which are part of the comprehensive analysis tools offered by InvestingPro. For more detailed analysis and tips on bluebird bio, Inc., visit https://www.investing.com/pro/BLUE.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.